Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.57 |
| ▸ | GSK3B | P49841 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415991 | 0.92 | PIK3CA (0.56) | PIK3CAPIK3R1GSK3BCYP2D6PIK3CB | |
| SCHEMBL4412974 | 0.92 | PIK3CA (0.61) | PIK3CAPIK3R1GSK3BPIK3CBPIK3CG | |
| SCHEMBL4415888 | 0.91 | PIK3CA (0.55) | PIK3CAPIK3R1GSK3BPIK3CBPIK3CG | |
| SCHEMBL4412531 | 0.91 | PIK3R1 (0.53) | PIK3CAPIK3R1GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4415624 | 0.90 | PIK3CA (0.54) | PIK3CAPIK3R1GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4422147 | 0.87 | PIK3CA (0.52) | PIK3CAPIK3R1GSK3BPIK3CBPIK3CG | |
| SCHEMBL4412535 | 0.80 | PIK3CA (0.63) | PIK3CAPIK3R1GSK3BPIK3CBPIK3CG | |
| SCHEMBL3574088 | 0.80 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6CSNK1A1GSK3A | |
| Hydrochloric Acid SCHEMBL4414192 | 0.80 | PIK3CA (0.62) | PIK3CAPIK3R1GSK3BPIK3CBPIK3CG | |
| SCHEMBL4415802 | 0.79 | GSK3B (0.51) | PIK3CAPIK3R1GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608653-B1 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-06-17 | — | — | EP | claimed |
| US-7393853-B2 | Use of substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives as therapeutic agents | SANOFI AVENTIS (FR) | 2008-07-01 | — | — | US | claimed |
| US-20070191384-A1 | Use of Substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] Pyrimidin-4-one Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | claimed |
| US-7217715-B2 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2007-05-15 | — | — | US | claimed |
| US-20060035910-A1 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | US | claimed |
| EP-1608653-B1 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-06-17 | — | — | EP | disclosed |
| US-7393853-B2 | Use of substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives as therapeutic agents | SANOFI AVENTIS (FR) | 2008-07-01 | — | — | US | disclosed |
| US-20070191384-A1 | Use of Substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] Pyrimidin-4-one Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
| US-7217715-B2 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2007-05-15 | — | — | US | disclosed |
| US-20060035910-A1 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1608653-A1 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083210-A1 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191384-A1 | Use of Substituted 8-Perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] Pyrimidin-4-one Derivatives as Therapeutic Agents | GSK3B, GSK3A, PSEN1 | PIK3CA 15/4885PIK3R1 18/4885GSK3B 1/4885 |
| US-20060035910-A1 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | PSEN1, PSEN2, GSK3A | PIK3CA 19/4885PIK3R1 23/4885GSK3B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.